Stephen Hahn

As Commissioner, within a week of passage of the 2020 United States federal budget, he quickly and unexpectedly changed the smoking age in the United States from 18 to 21.

On March 1, 2020, Vice President Mike Pence and Health and Human Services Secretary Alex Azar announced the addition of Hahn to the White House Coronavirus Taskforce.

In April 2020, Hahn instructed Federal Emergency Management Administrator Peter Gaynor "to distribute hydroxychloroquine to pharmacies nationwide, even though [an Emergency Use Authorization issued by the FDA] did not provide for outpatient use of the drug," according to a whistleblower complaint filed by HHS infectious disease expert Rick Bright. Hydroxychloroquine was later linked to multiple deaths of covid-19 patients.

On November 1, 2019, U.S. President Donald Trump announced his intent to nominate Hahn to be Commissioner of Food and Drugs Administration . On December 3, 2019, the Senate Health Education Labor and Pensions Committee voted 18 to 5 in favor of Dr. Hahn leading the FDA. On December 12, 2019, the United States Senate confirmed his nomination by a 72–18 vote. Hahn was sworn in on December 17, 2019.

In 2015, Hahn became the chair of radiation oncology at the University of Texas MD Anderson Cancer Center in Houston, where he oversaw the Departments of Clinical Radiation Oncology, Radiation Physics, and Radiation Biology. In 2018, Hahn was appointed as the Chief Medical Executive of MD Anderson Cancer Center. During this period as an active clinician, Hahn specialized in treating thoracic, sarcomatous, and genitourinary cancers, as well as the use of photodynamic therapy for the treatment of pre-invasive and invasive malignancies.

In 1996, Hahn joined the University of Pennsylvania School of Medicine as a radiation and medical oncologist as well as a researcher funded by the National Institutes of Health (NIH). As eventual Vice-Chair for Research in the Department of Radiation Oncology at Penn and Principal Investigator of National Cancer Institute grants, Hahn led the expansion of the Department's research base. In 2013, he was awarded status as a fellow in the American Society for Radiation Oncology (ASTRO). He then held the Department of Radiation Oncology's fourth endowed Henry Pancoast Professorship as Department Chair until 2014.[1] During that time, Hahn assisted with the Department's scandal involving brachytherapy at the Veterans Affairs Hospital in Philadelphia, which was staffed with University of Pennsylvania faculty, all while securing increased research funding during a transition period in 2007-08 into the new Perelman Center for Advanced Medicine Robert's Proton Center, which remains the largest proton therapy center associated with a university teaching hospital in the world. Hahn remains Board Certified in Internal Medicine, Medical Oncology, and Radiation Oncology.

After completing his fellowship, Hahn worked as a medical oncologist in Santa Rosa, California. He was then recruited by his mentor, Dr. Eli J. Glatstein to complete a separate residency in radiation oncology at the NIH between 1991 and 1994, where he eventually attained the rank of commander in the U.S. Public Health Service Commissioned Corps between 1989–1995. During the period of 1993–1999, he served as chief of NCI's Prostate Cancer Clinic in the Clinical Pharmacology Branch.

Hahn received a BA in Biology from Rice University in 1980, and an MD from Temple University in 1984. After graduating from medical school, Hahn completed an internal medicine residency at the University of San Francisco School of Medicine where he eventually served as chief resident before embarking on a fellowship in medical oncology at the National Institutes of Health (NIH).

Stephen Michael Hahn (born January 22, 1960) is an American physician who has served as the Commissioner of Food and Drugs since December 2019. Before becoming Commissioner, he was a radiation oncologist serving as Chief Medical Executive of the MD Anderson Cancer Center.